Monoamine oxidase A (MAOA) is an enzyme involved in the metabolism of the monoamines, eg 5-HT and noradrenaline. It converts the monoamines into their corresponding carboxylic acid via an aldehyde intermediate. MAOA regulates both the free intraneuronal concentration and the releasable stores of 5-HT and noradrenaline. MAOA inhibitors bind to and inhibit MAOA, preventing monoamine degradation. This results in greater stores of monoamines available for release. MAOA inhibitors are used in the treatment of depression. It has been proposed that MAO inhibitors treat depression by preventing monoamine degradation and delaying downregulation of beta-andrenoceptors and 5-HT2 receptors.
Click here: Discover the role of MAO-A inhibitors in depression treatment
Related content
One hypothesis of the cycle of anhedonia (loss of interest or pleasure) in patients with depression is illustrated in this image; this hypothesis comes from a series of experiments performed on a sample of psychology students.
As adjunctive treatment in MDD, some dopamine–serotonin receptor antagonists are associated with sedating side effects, while others are more often associated with ‘activating’ side effects.